The Library
Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid : a pragmatic, non-inferiority, randomised controlled trial
Tools
Tools
Tools
BLISTER study group (Including: Williams, Hywel C., Wojnarowska, Fenella, Kirtschig, Gudula, Mason, James, Godec, Thomas R., Schmidt, Enno, Chalmers, Joanne R., Childs, Margaret, Walton, Shernaz, Harman, Karen, Chapman, Anna, Whitham, Diane and Nunn, Andrew J.). (2017) Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid : a pragmatic, non-inferiority, randomised controlled trial. The Lancet, 389 (10079). pp. 1630-1638. doi:10.1016/S0140-6736(17)30560-3 ISSN 0140-6736.
|
PDF
WRAP_PIIS0140673617305603.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (812Kb) | Preview |
Official URL: http://dx.doi.org/10.1016/S0140-6736(17)30560-3
Abstract
Background
Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids.
Methods
We did a pragmatic, multicentre, parallel-group randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Participants were randomly assigned to doxycycline (200 mg per day) or prednisolone (0·5 mg/kg per day) using random permuted blocks of randomly varying size, and stratified by baseline severity (3–9, 10–30, and >30 blisters for mild, moderate, and severe disease, respectively). Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted during weeks 1–3. The non-inferiority primary effectiveness outcome was the proportion of participants with three or fewer blisters at 6 weeks. We assumed that doxycycline would be 25% less effective than corticosteroids with a 37% acceptable margin of non-inferiority. The primary safety outcome was the proportion with severe, life-threatening, or fatal (grade 3–5) treatment-related adverse events by 52 weeks. Analysis (modified intention to treat [mITT] for the superiority safety analysis and mITT and per protocol for non-inferiority effectiveness analysis) used a regression model adjusting for baseline disease severity, age, and Karnofsky score, with missing data imputed. The trial is registered at ISRCTN, number ISRCTN13704604.
Findings
Between March 1, 2009, and Oct 31, 2013, 132 patients were randomly assigned to doxycycline and 121 to prednisolone from 54 UK and seven German dermatology centres. Mean age was 77·7 years (SD 9·7) and 173 (68%) of 253 patients had moderate-to-severe baseline disease. For those starting doxycycline, 83 (74%) of 112 patients had three or fewer blisters at 6 weeks compared with 92 (91%) of 101 patients on prednisolone, an adjusted difference of 18·6% (90% CI 11·1–26·1) favouring prednisolone (upper limit of 90% CI, 26·1%, within the predefined 37% margin). Related severe, life-threatening, and fatal events at 52 weeks were 18% (22 of 121) for those starting doxycycline and 36% (41 of 113) for prednisolone (mITT), an adjusted difference of 19·0% (95% CI 7·9–30·1), p=0·001.
Interpretation
Starting patients on doxycycline is non-inferior to standard treatment with oral prednisolone for short-term blister control in bullous pemphigoid and significantly safer in the long-term.
| Item Type: | Journal Article | ||||||
|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > R Medicine (General) R Medicine > RL Dermatology |
||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||
| Library of Congress Subject Headings (LCSH): | Blisters -- Treatment, Skin -- Diseases -- Treatment, Clinical trials | ||||||
| Journal or Publication Title: | The Lancet | ||||||
| Publisher: | Lancet Publishing Group | ||||||
| ISSN: | 0140-6736 | ||||||
| Official Date: | 22 April 2017 | ||||||
| Dates: |
|
||||||
| Volume: | 389 | ||||||
| Number: | 10079 | ||||||
| Page Range: | pp. 1630-1638 | ||||||
| DOI: | 10.1016/S0140-6736(17)30560-3 | ||||||
| Status: | Peer Reviewed | ||||||
| Publication Status: | Published | ||||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||||
| Date of first compliant deposit: | 8 March 2017 | ||||||
| Date of first compliant Open Access: | 9 March 2017 | ||||||
| Funder: | National Institute for Health Research Health Technology Assessment (Great Britain) (NIHR HTA) |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
